Filing Flows › Health Care › Equillium (EQ)
Equillium (EQ) earnings and revenue breakdown
Latest: Q4 2024 · 10-K filed Mar 27, 2025 · Equillium (EQ) Q4 2024 earnings results →
Q4 2024 Revenue down 52% year over year to $4.4M · 132¢ of every $1 of revenue lost · operating margin -107.0%
Equillium made $4.4M in Q4 2024 (-52% Y/Y). Operating margin -107.0%, net loss $5.8M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-K filed Mar 27, 2025.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $4.4M in Q4 2024, down 52% year over year and down 64% from the previous quarter.
Operating costs exceeded revenue by $4.7M, an operating margin of -107.0%. Total costs fell 27% while revenue fell 52%. The quarter ended with a net loss of $5.8M, wider than the previous quarter's $7K loss.
Operating cash flow was −$3.3M. Non-cash charges added back $35K of depreciation and $821K of share-based compensation. Working capital and other items added $1.6M. Capital expenditures of $4K exceeded it, leaving free cash flow of −$3.3M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q4 2024 | 10-K | Mar 27, 2025 | $4.4M | -52% | -107.0% | −$5.8M | −$3.3M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Equillium
Equillium is a biotechnology innovator with a mission to develop highly impactful therapies to treat severe autoimmune and inflammatory disorders.
In its own words, from its 8-K, filed Aug 13, 2026.
Equillium against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -52% against the peers' median +7%. Operating margin: -107.0% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| EQ Equillium | Q4 2024 | $4.4M | -52% | -107.0% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Equillium 10-K on SEC EDGAR · CIK 1746466 · Pharmaceutical Preparations
13F: who owns EQ and who is buying
More on EQ
History
Every quarter: Q4 2024 results